Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis.
Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H, Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Kubo K, Yagasaki F, Higa T, Taguchi H, Tobita T, Akiyama H, Takeshita A, Wang YH, Motoji T, Ohno R, Nakamura Y. Okutsu J, et al. Among authors: kaneta y. Mol Cancer Ther. 2002 Oct;1(12):1035-42. Mol Cancer Ther. 2002. PMID: 12481426
Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
Toyota A, Goto M, Miyamoto M, Nagashima Y, Iwasaki S, Komatsu T, Momose T, Yoshida K, Tsukada T, Matsufuji T, Ohno A, Suzuki M, Ubukata O, Kaneta Y. Toyota A, et al. Among authors: kaneta y. Biochem Biophys Res Commun. 2022 Sep 17;621:157-161. doi: 10.1016/j.bbrc.2022.07.008. Epub 2022 Jul 7. Biochem Biophys Res Commun. 2022. PMID: 35839742
Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity.
Taniguchi T, Inagaki H, Baba D, Yasumatsu I, Toyota A, Kaneta Y, Kiga M, Iimura S, Odagiri T, Shibata Y, Ueda K, Seo M, Shimizu H, Imaoka T, Nakayama K. Taniguchi T, et al. Among authors: kaneta y. ACS Med Chem Lett. 2019 Mar 15;10(5):737-742. doi: 10.1021/acsmedchemlett.8b00631. eCollection 2019 May 9. ACS Med Chem Lett. 2019. PMID: 31097992 Free PMC article.
Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma.
Takano K, Munehira Y, Hatanaka M, Murakami R, Shibata Y, Shida T, Takeuchi K, Takechi S, Tabata T, Shimada T, Kishikawa S, Matsui Y, Ubukata O, Seki T, Kaneta Y. Takano K, et al. Among authors: kaneta y. Mol Cancer Ther. 2023 Mar 2;22(3):317-332. doi: 10.1158/1535-7163.MCT-22-0306. Mol Cancer Ther. 2023. PMID: 36622773
42 results